Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

被引：2
|
作者：
Vicente, Alana [1 ]
Gutierrez-Rodrigues, Fernanda [1 ]
Giudice, Valentina [1 ]
Wu, Zhijie [1 ]
Kajigaya, Sachiko [1 ]
Ibanez, Maria del Pilar Fernandez [1 ]
Albitar, Maher [2 ]
Weinstein, Barbara [1 ]
Calvo, Katherine R. [1 ]
Townsley, Danielle M. [1 ]
Scheinberg, Phillip [3 ]
Dunbar, Cynthia E. [1 ]
Young, Neal S. [1 ]
Winkler, Thomas [1 ]
机构：
[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[2] NeoGenomics, Valley Ctr, CA USA
[3] Hosp A Beneficencia Portuguesa, Div Hematol, Sao Paulo, Brazil
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119780
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
229
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low-or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Kadia, Tapan
    Borthakur, Gautam
    DiNardo, Courtney
    Miller, Darla
    Estrov, Zeev
    Pemmaraju, Naveen
    Daver, Naval
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [32] EGCG IMPROVES INEFFECTIVE HEMATOPOIESIS IN A MOUSE MODEL OF MYELODYSPLASTIC SYNDROME
    Della Via, F.
    Ferro, K.
    Santos, I.
    Amor, N.
    De Souza, F.
    De Prax, M.
    Saad, S.
    LEUKEMIA RESEARCH, 2023, 128
  • [33] A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece
    Pappa, Vasiliki
    Anagnostopoulos, Achilles
    Bouronikou, Eleni
    Briasoulis, Evangelos
    Kotsianidis, Ioannis
    Pagoni, Maria
    Zikos, Panagiotis
    Tsionos, Konstantinos
    Viniou, Nora
    Meletis, John
    Papadaki, Helen
    Kioumi, Anna
    Galanopoulos, Athanasios
    Vervessou, Elisavet-Christine
    Poulakidas, Elias
    Karmas, Panagiotis
    Karvounis, Kiki
    Symeonidis, Argiris
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (02) : 184 - 195
  • [34] Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
    List, AF
    Brasfield, F
    Heaton, R
    GlinsmannGibson, B
    Crook, L
    Taetle, R
    Capizzi, R
    BLOOD, 1997, 90 (09) : 3364 - 3369
  • [35] Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients
    Breccia, Massimo
    Loglisci, Giuseppina
    Salaroli, Adriano
    Finsinger, Paola
    Serrao, Alessandra
    Petrucci, Luigi
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2012, 36 (05) : 546 - 547
  • [36] A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece
    Vasiliki Pappa
    Achilles Anagnostopoulos
    Eleni Bouronikou
    Evangelos Briasoulis
    Ioannis Kotsianidis
    Maria Pagoni
    Panagiotis Zikos
    Konstantinos Tsionos
    Nora Viniou
    John Meletis
    Helen Papadaki
    Anna Kioumi
    Athanasios Galanopoulos
    Elisavet-Christine Vervessou
    Elias Poulakidas
    Panagiotis Karmas
    Kiki Karvounis
    Argiris Symeonidis
    International Journal of Hematology, 2017, 105 : 184 - 195
  • [37] Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
    Kantarjian, Hagop M.
    Giles, Francis J.
    Greenberg, Peter L.
    Paquette, Ron L.
    Wang, Eunice S.
    Gabrilove, Janice L.
    Garcia-Manero, Guillermo
    Hu, Kuolung
    Franklin, Janet L.
    Berger, Dietmar P.
    BLOOD, 2010, 116 (17) : 3163 - 3170
  • [38] Combination of pentoxifylline (PTX), ciprofloxacin (Cipro), dexamethasone (PCD) with amifostine improves ineffective hematopoiesis in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Andric, T
    Qawi, H
    Venugopal, P
    Gezer, S
    Gregory, SA
    Hines, C
    Mundle, S
    Ali, A
    Shetty, V
    Mativi, BY
    Dar, S
    Loew, J
    Robin, EL
    Kozloff, M
    Galvez, A
    Rifkin, SD
    Alston, D
    Hernandez, BM
    Shah, R
    BLOOD, 1997, 90 (10) : 367 - 367
  • [39] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    BLOOD, 2017, 130
  • [40] A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result
    Chuncharunee, Suporn
    Kanitsap, Nonglak
    Suwanban, Tawatchai
    Khuhapinant, Archrob
    Uaprasert, Noppacharn
    Chansung, Kanchana
    Rattarittamrong, Ekarat
    Wongkhantee, Somchai
    Siritanaratanakul, Noppadol
    Norasetthada, Lalita
    Nakorn, Thanyaphong Na
    Charnwiboonsri, Chadchai
    BLOOD, 2016, 128 (22)
12345